Medicine and Dentistry
Ovarian Cancer
100%
Neoplasm
69%
Diseases
48%
Uterine Cancer
46%
Cervical Cancer
46%
Malignant Neoplasm
45%
Krukenberg Tumor
45%
Cancer
28%
Recurrent Disease
26%
Gynecological Oncology
24%
Overall Survival
22%
Female Genital Tract Cancer
21%
Metastatic Carcinoma
18%
Radiation Therapy
17%
Endometrium Carcinoma
15%
Cancer Cell
14%
Pelvis
14%
Breast Cancer
13%
Progression Free Survival
13%
Cervix
12%
Cisplatin
11%
Ovarian Tumor
10%
Biological Marker
10%
Serous Carcinoma
10%
Tumor Progression
10%
Clinical Trial
10%
Retroperitoneal Lymph Node Dissection
10%
Radical Hysterectomy
9%
Paclitaxel
9%
Oncology
9%
Hysterectomy
9%
Surgery
9%
Carcinoma
9%
Adenocarcinoma
9%
Cancer Therapy
8%
Hazard Ratio
8%
Quality of Life
8%
BRCA1
8%
Wart Virus
8%
Lymph Node
7%
Cytoreductive Surgery
7%
Tumor Cell
7%
Neoadjuvant Chemotherapy
7%
Minimal Residual Disease
7%
PARP Inhibitor
7%
In Vitro
7%
Health Care Cost
7%
Hereditary Nonpolyposis Colorectal Cancer
7%
Prognostic Factor
6%
Survival Rate
6%
CA-125
6%
Carboplatin
6%
Bevacizumab
6%
Squamous Cell Carcinoma
6%
Lymph Duct
6%
Adjuvant Therapy
6%
Laparotomy
6%
Biopsy Technique
6%
Cancer Risk
6%
Small Interfering RNA
5%
Sentinel Lymph Node
5%
microRNA
5%
Fallopian Tube
5%
Genetic Screening
5%
Uterine Cervix Carcinoma
5%
BRCA2
5%
Protein P53
5%
Oncologist
5%
Chemoradiotherapy
5%
Meta-Analysis
5%
Primary Tumor
5%
Targeted Therapy
5%
Doxorubicin
5%
Minimally Invasive Procedure
5%
Carcinogenesis
5%
Laparoscopic Surgery
5%
Programmed Cell Death
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
57%
Neoplasm
42%
Malignant Neoplasm
36%
Chemotherapy
24%
Ovary Carcinoma
24%
Diseases
24%
Uterine Cervix Cancer
15%
Endometrium Cancer
14%
Small Interfering RNA
12%
Paclitaxel
11%
Recurrent Disease
11%
Overall Survival
11%
Cisplatin
10%
Tumor Growth
9%
Progression Free Survival
9%
Biological Marker
7%
Breast Cancer
7%
Carcinoma
6%
Doxorubicin
6%
microRNA
6%
Clinical Trial
6%
Endometrium Carcinoma
6%
Bevacizumab
6%
Carboplatin
5%
Metastasis
5%
Vasculotropin
5%
Female Genital Tract Cancer
5%
Keyphrases
Ovarian Cancer
50%
Tumor
28%
Endometrial Cancer
23%
Cervical Cancer
18%
Chemotherapy
16%
Epithelial Ovarian Cancer
15%
Overall Survival
13%
Gynecological Cancer
12%
Confidence Interval
10%
In Cancer
9%
Advanced Ovarian Cancer
9%
Gynecologic Malignancies
9%
Ovarian Cancer Cells
8%
Ovarian Carcinoma
8%
Cisplatin
8%
Small Interfering RNA (siRNA)
7%
Progression-free Survival
7%
Tumor Growth
6%
Cervical Carcinoma
6%
Neoadjuvant Chemotherapy
6%
Endometrial Carcinoma
6%
High-grade Serous Ovarian Cancer (HGSOC)
6%
Hazard Ratio
6%
Breast Cancer
6%
PARP Inhibitor (PARPi)
6%
Recurrent Disease
6%
Bevacizumab
5%
Gynecologic Oncology Group
5%
Paclitaxel
5%
Ovarian Cancer Patients
5%
Early-stage Cervical Cancer
5%
Phase II Trial
5%